{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/glaucoma/","result":{"data":{"firstChapter":{"id":"b70753e1-40bf-5d64-8042-80499a3a3663","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 055519f2-380e-4056-b8be-21bb4cdf651c --><h1>Glaucoma: Summary</h1><!-- end field 055519f2-380e-4056-b8be-21bb4cdf651c -->","htmlStringContent":"<!-- begin item cc51cd5b-2918-4085-ae6f-1fb47b3dbdd7 --><!-- begin field 21dc451b-dfb5-44dc-93c5-adb06bf1c263 --><ul><li>Glaucoma is a group of eye diseases that cause progressive optic neuropathy.</li><li>Glaucoma is commonly associated with raised intraocular pressure (IOP) and characterized by:<ul><li>Visual field defects. </li><li>Changes to the optic nerve head such as pathological cupping or pallor of the optic disc.</li></ul></li><li>Ocular hypertension is consistently or recurrently raised IOP but with no signs of glaucoma. It affects 3–5% of people in the UK over 40 years. It requires monitoring as it may progress to glaucoma.</li><li>Glaucoma can be classified according to:<ul><li>Age of onset: congenital, infantile, juvenile, or adult.</li><li>Cause: primary (no known cause) or secondary.</li><li>Rate of onset: acute, subacute, or chronic.</li><li>The anterior chamber angle between the iris and cornea: being either open or closed.</li></ul></li><li>Primary open angle glaucoma (POAG) is the most common type that mainly affects older people, occurring in about 2% of people in the UK over 40 years. POAG:<ul><li>Is usually insidious in onset, and follows a chronic course. </li><li>Usually affects both eyes. </li><li>Is typically associated with raised IOP that is thought to damage optic nerve fibres, but occurs in a significant minority of people with normal IOP. </li></ul></li><li>Primary angle closure glaucoma (PACG) mainly affects older people, occurring in about 0.4% of people in the UK over 40 years. Most people with PACG have asymptomatic chronic PACG.</li><li>Acute angle closure (which may quickly progress to glaucoma) should be suspected in a person with an acute painful red eye, and in particular who:<ul><li>Is female, Asian, long-sighted, or of older age.</li><li>Has a history of episodes of blurred vision, headaches, or eye pain associated with nausea and seeing halos around lights; these symptoms typically occur in the evening and are relieved by sleeping.</li><li>May also have: headache, nausea, vomiting; lights are seen surrounded by halos — caused by an oedematous cornea; semi-dilated and fixed pupil; tender, hard eye; impaired visual acuity.</li></ul></li><li>If acute angle closure is suspected, the person should be admitted for ophthalmology assessment.<ul><li>If immediate admission is not possible, emergency treatment should be started in primary care. </li><li>The person should lie flat with their face up and head not supported by pillows. </li><li>If available, pilocarpine drops should be administered — one drop of 2% in blue eyes or 4% in brown eyes; acetazolamide 500 mg given orally (if no contraindications); and analgesia and an anti-emetic provided, if required.</li></ul></li><li>If a primary healthcare professional suspects chronic glaucoma, they should refer the person to an optometrist or ophthalmologist.</li><li>The main complication of untreated glaucoma is irreversible loss of vision (partial or complete). Appropriate treatment reduces the risk of progression of the disease.</li><li>Treatment of all types of glaucoma, and of ocular hypertension when indicated, is normally initiated and monitored by specialists. The mainstay of treatment is to reduce IOP. This is usually done with eye drops but sometimes laser or surgical treatments are required.</li></ul><!-- end field 21dc451b-dfb5-44dc-93c5-adb06bf1c263 --><!-- end item cc51cd5b-2918-4085-ae6f-1fb47b3dbdd7 -->","topic":{"id":"2f2ce020-977b-56c2-bfe0-79af338099b2","topicId":"3f1d1b43-0970-4917-b518-15a04dfd4397","topicName":"Glaucoma","slug":"glaucoma","aliases":[],"chapters":[{"id":"b70753e1-40bf-5d64-8042-80499a3a3663","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"99932988-c7ac-5201-8a03-324771c52186","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"4665a282-8076-541c-8fdb-d884f514e73a","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"90547efd-385b-5418-95dc-840a239bb4b6","slug":"changes","fullItemName":"Changes"},{"id":"744db240-54ad-5b2b-bde1-fbf5f82dd75c","slug":"update","fullItemName":"Update"}]},{"id":"1b9b2a0b-c1eb-5850-81a4-594deb443996","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"d96d012a-8a50-5197-a3bc-80be922d4ec3","slug":"goals","fullItemName":"Goals"},{"id":"ab168d63-48cb-5e39-af87-b20be5416a2b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1371aed7-3648-50af-9b62-765d61209340","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e5d9b1dc-20e2-5c90-807b-c86643d03e27","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"634d007b-489f-5899-be8c-e79e2c12d416","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"895cf400-6256-5dd3-9e84-20a916980e46","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"05123836-33c6-55ab-87b4-82c858ac280b","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"e281b4eb-d1e1-5e3a-ac1e-ba1ce5a60a71","slug":"definition","fullItemName":"Definition"},{"id":"1d1f8e60-4614-5dcc-a66d-9019ca4e6e03","slug":"anatomy-physiology","fullItemName":"Anatomy and physiology"},{"id":"00e7c765-c989-527f-b21f-29ad09409af8","slug":"classification","fullItemName":"Classification"},{"id":"855a9d74-8bb6-54d9-bfc9-5c385ae0f3f4","slug":"causes","fullItemName":"Causes"},{"id":"89456b4f-1b83-5bd6-ba80-018c1171090d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"37e8081e-c003-5262-a267-bf22817b2d3d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"592dbfb6-31cc-55a6-a38e-b77abbd29565","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f95b1f20-8f4d-5e8f-9e11-426b2a59246a","slug":"complications","fullItemName":"Complications"}]},{"id":"86e2bb04-52a3-5765-8605-aa439e65cf40","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"c3238d06-745f-57aa-b5f9-69dc42896f15","slug":"primary-angle-closure-glaucoma","fullItemName":"Primary angle closure glaucoma"},{"id":"f7c27cd1-50e2-5977-9f46-b1ae6e37f8c6","slug":"ocular-hypertension-primary-open-angle-glaucoma","fullItemName":"Ocular hypertension and primary open angle glaucoma"},{"id":"8f240bf4-5d3c-57ba-a2f7-5e0b82983e5c","slug":"opportunistic-testing-for-glaucoma","fullItemName":"Opportunistic testing for glaucoma"}]},{"id":"c621d247-f521-559a-93ce-c62c3ab5fd2b","slug":"management","fullItemName":"Management","subChapters":[{"id":"1e08cb89-b766-5a2f-9853-4406baa8635c","slug":"acute-angle-closure-angle-closure-glaucoma","fullItemName":"Scenario: Acute angle closure and angle closure glaucoma"},{"id":"803a56e6-2082-5ccc-add9-0d7bd9f32f6a","slug":"primary-open-angle-glaucoma-intraocular-hypertension","fullItemName":"Scenario: Primary open angle glaucoma and intraocular hypertension"}]},{"id":"2d512acb-6e34-566f-8f5f-90eb0d0c8431","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"d784c3ec-391a-5275-a286-56b128e61629","slug":"topical-prostaglandin-analogues-prostamides","fullItemName":"Topical prostaglandin analogues and prostamides"},{"id":"7d644d35-69fa-5a6f-8ceb-fab24019dcee","slug":"topical-beta-blockers","fullItemName":"Topical beta-blockers"},{"id":"7a8c1c4a-8a2d-5555-828d-58b50a740f88","slug":"topical-sympathomimetics","fullItemName":"Topical sympathomimetics"},{"id":"9a1dce0a-a42d-5d80-8ded-a8444facf830","slug":"carbonic-anhydrase-inhibitors","fullItemName":"Carbonic anhydrase inhibitors"},{"id":"efeb705d-eba6-581c-93ad-0916f0aed1c4","slug":"topical-miotics","fullItemName":"Topical miotics"}]},{"id":"657fc5fb-6ac1-5cfe-8fde-6a6eaf21e17b","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"14521c62-39fa-5ea2-9b3b-ba4a79d55565","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"4d0bdf94-c9fe-564d-bd78-4e6e957019c7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4dec5995-8a6e-599f-a3ec-4401dda0f2fc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fbee715b-cedc-51e6-91f9-00319ab7944f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"802ad5b9-1cd1-59e9-8b22-2239d0b31c19","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4211d06e-9a65-51ea-ac4d-d35ca789f223","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"85b73253-be63-5a83-8948-152e3b5a51f7","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"2f2ce020-977b-56c2-bfe0-79af338099b2","topicId":"3f1d1b43-0970-4917-b518-15a04dfd4397","topicName":"Glaucoma","slug":"glaucoma","aliases":[],"topicSummary":"Glaucoma is a group of eye diseases that cause progressive optic neuropathy.Glaucoma is commonly associated with raised intraocular pressure (IOP)","lastRevised":"Last revised in November 2020","nextPlannedReviewBy":"2025-06-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2025-05","nextPlannedReviewByDisplay":"May 2025","specialities":[{"id":"485bdd1b-4437-5374-838e-f1f1db61a424","name":"Eyes","slug":"eyes"}],"chapters":[{"id":"b70753e1-40bf-5d64-8042-80499a3a3663","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"99932988-c7ac-5201-8a03-324771c52186","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"4665a282-8076-541c-8fdb-d884f514e73a","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"90547efd-385b-5418-95dc-840a239bb4b6","slug":"changes","fullItemName":"Changes"},{"id":"744db240-54ad-5b2b-bde1-fbf5f82dd75c","slug":"update","fullItemName":"Update"}]},{"id":"1b9b2a0b-c1eb-5850-81a4-594deb443996","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"d96d012a-8a50-5197-a3bc-80be922d4ec3","slug":"goals","fullItemName":"Goals"},{"id":"ab168d63-48cb-5e39-af87-b20be5416a2b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1371aed7-3648-50af-9b62-765d61209340","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e5d9b1dc-20e2-5c90-807b-c86643d03e27","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"634d007b-489f-5899-be8c-e79e2c12d416","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"895cf400-6256-5dd3-9e84-20a916980e46","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"05123836-33c6-55ab-87b4-82c858ac280b","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"e281b4eb-d1e1-5e3a-ac1e-ba1ce5a60a71","slug":"definition","fullItemName":"Definition"},{"id":"1d1f8e60-4614-5dcc-a66d-9019ca4e6e03","slug":"anatomy-physiology","fullItemName":"Anatomy and physiology"},{"id":"00e7c765-c989-527f-b21f-29ad09409af8","slug":"classification","fullItemName":"Classification"},{"id":"855a9d74-8bb6-54d9-bfc9-5c385ae0f3f4","slug":"causes","fullItemName":"Causes"},{"id":"89456b4f-1b83-5bd6-ba80-018c1171090d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"37e8081e-c003-5262-a267-bf22817b2d3d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"592dbfb6-31cc-55a6-a38e-b77abbd29565","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f95b1f20-8f4d-5e8f-9e11-426b2a59246a","slug":"complications","fullItemName":"Complications"}]},{"id":"86e2bb04-52a3-5765-8605-aa439e65cf40","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"c3238d06-745f-57aa-b5f9-69dc42896f15","slug":"primary-angle-closure-glaucoma","fullItemName":"Primary angle closure glaucoma"},{"id":"f7c27cd1-50e2-5977-9f46-b1ae6e37f8c6","slug":"ocular-hypertension-primary-open-angle-glaucoma","fullItemName":"Ocular hypertension and primary open angle glaucoma"},{"id":"8f240bf4-5d3c-57ba-a2f7-5e0b82983e5c","slug":"opportunistic-testing-for-glaucoma","fullItemName":"Opportunistic testing for glaucoma"}]},{"id":"c621d247-f521-559a-93ce-c62c3ab5fd2b","slug":"management","fullItemName":"Management","subChapters":[{"id":"1e08cb89-b766-5a2f-9853-4406baa8635c","slug":"acute-angle-closure-angle-closure-glaucoma","fullItemName":"Scenario: Acute angle closure and angle closure glaucoma"},{"id":"803a56e6-2082-5ccc-add9-0d7bd9f32f6a","slug":"primary-open-angle-glaucoma-intraocular-hypertension","fullItemName":"Scenario: Primary open angle glaucoma and intraocular hypertension"}]},{"id":"2d512acb-6e34-566f-8f5f-90eb0d0c8431","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"d784c3ec-391a-5275-a286-56b128e61629","slug":"topical-prostaglandin-analogues-prostamides","fullItemName":"Topical prostaglandin analogues and prostamides"},{"id":"7d644d35-69fa-5a6f-8ceb-fab24019dcee","slug":"topical-beta-blockers","fullItemName":"Topical beta-blockers"},{"id":"7a8c1c4a-8a2d-5555-828d-58b50a740f88","slug":"topical-sympathomimetics","fullItemName":"Topical sympathomimetics"},{"id":"9a1dce0a-a42d-5d80-8ded-a8444facf830","slug":"carbonic-anhydrase-inhibitors","fullItemName":"Carbonic anhydrase inhibitors"},{"id":"efeb705d-eba6-581c-93ad-0916f0aed1c4","slug":"topical-miotics","fullItemName":"Topical miotics"}]},{"id":"657fc5fb-6ac1-5cfe-8fde-6a6eaf21e17b","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"14521c62-39fa-5ea2-9b3b-ba4a79d55565","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"4d0bdf94-c9fe-564d-bd78-4e6e957019c7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4dec5995-8a6e-599f-a3ec-4401dda0f2fc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fbee715b-cedc-51e6-91f9-00319ab7944f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"802ad5b9-1cd1-59e9-8b22-2239d0b31c19","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4211d06e-9a65-51ea-ac4d-d35ca789f223","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"85b73253-be63-5a83-8948-152e3b5a51f7","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"2f2ce020-977b-56c2-bfe0-79af338099b2"}},"staticQueryHashes":["3666801979"]}